$12.23
0[0.00%]
At close: Apr 25
$12.23
0[0.00%]
PreMarket: 4:20PM EDT
NovoCure
(NASDAQ:NVCR)NovoCure Stock (NASDAQ:NVCR), Analyst Ratings, Price Targets, Predictions
NovoCure Ltd has a consensus price target of $70.08, established from looking at the 42 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, Wells Fargo, and HC Wainwright & Co. on April 10, 2024, April 3, 2024, and March 27, 2024. With an average price target of $31.33 between Piper Sandler, Wells Fargo, and HC Wainwright & Co., there's an implied 156.20% upside for NovoCure Ltd from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Wells Fargo
HC Wainwright & Co.
JP Morgan
Evercore ISI Group
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for NovoCure
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | NVCR | Buy Now | NovoCure | $12.23 | 128.95% | Piper Sandler | Jason Bednar | $25 → $28 | Reiterates | Overweight → Overweight | Get Alert |
| 04/03/2024 | NVCR | Buy Now | NovoCure | $12.23 | 243.42% | Wells Fargo | Larry Biegelsen | $49 → $42 | Maintains | Overweight | Get Alert |
| 03/27/2024 | NVCR | Buy Now | NovoCure | $12.23 | 96.24% | HC Wainwright & Co. | Emily Bodnar | $22 → $24 | Maintains | Neutral | Get Alert |
| 03/19/2024 | NVCR | Buy Now | NovoCure | $12.23 | 39% | JP Morgan | Jessica Fye | $15 → $17 | Maintains | Neutral | Get Alert |
| 03/12/2024 | NVCR | Buy Now | NovoCure | $12.23 | 79.89% | HC Wainwright & Co. | Emily Bodnar | → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 02/23/2024 | NVCR | Buy Now | NovoCure | $12.23 | 22.65% | Evercore ISI Group | Vijay Kumar | $14 → $15 | Maintains | In-Line | Get Alert |
| 02/22/2024 | NVCR | Buy Now | NovoCure | $12.23 | 79.89% | HC Wainwright & Co. | Emily Bodnar | $21 → $22 | Maintains | Buy | Get Alert |
| 08/29/2023 | NVCR | Buy Now | NovoCure | $12.23 | 300.65% | Wells Fargo | Larry Biegelsen | $102 → $49 | Maintains | Overweight | Get Alert |
| 08/28/2023 | NVCR | Buy Now | NovoCure | $12.23 | 104.42% | HC Wainwright & Co. | Emily Bodnar | → $25 | Downgrade | Buy → Neutral | Get Alert |
| 08/08/2023 | NVCR | Buy Now | NovoCure | $12.23 | 267.95% | Piper Sandler | Jason Bednar | → $45 | Upgrade | Neutral → Overweight | Get Alert |
| 08/04/2023 | NVCR | Buy Now | NovoCure | $12.23 | 317.01% | SVB Leerink | Jonathan Chang | → $51 | Initiates | → Outperform | Get Alert |
| 07/31/2023 | NVCR | Buy Now | NovoCure | $12.23 | 169.83% | Evercore ISI Group | Vijay Kumar | → $33 | Upgrade | Underperform → In-Line | Get Alert |
| 07/28/2023 | NVCR | Buy Now | NovoCure | $12.23 | 734.01% | Wells Fargo | Larry Biegelsen | $104 → $102 | Maintains | Overweight | Get Alert |
| 07/27/2023 | NVCR | Buy Now | NovoCure | $12.23 | 595.01% | HC Wainwright & Co. | Emily Bodnar | → $85 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2023 | NVCR | Buy Now | NovoCure | $12.23 | 406.95% | Piper Sandler | Jason Bednar | $67 → $62 | Maintains | Neutral | Get Alert |
| 06/07/2023 | NVCR | Buy Now | NovoCure | $12.23 | 276.12% | Wedbush | David Nierengarten | $53 → $46 | Upgrade | Underperform → Neutral | Get Alert |
| 06/06/2023 | NVCR | Buy Now | NovoCure | $12.23 | 676.78% | Truist Securities | Gregory Fraser | → $95 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | NVCR | Buy Now | NovoCure | $12.23 | 840.31% | HC Wainwright & Co. | Emily Bodnar | → $115 | Reiterates | → Buy | Get Alert |
| 05/16/2023 | NVCR | Buy Now | NovoCure | $12.23 | 750.37% | Wells Fargo | Larry Biegelsen | $70 → $104 | Upgrade | Equal-Weight → Overweight | Get Alert |
FAQ
What is the target price for NovoCure (NVCR)?
The latest price target for NovoCure (NASDAQ: NVCR) was reported by Piper Sandler on April 10, 2024. The analyst firm set a price target for $28.00 expecting NVCR to rise to within 12 months (a possible 128.95% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NovoCure (NVCR)?
The latest analyst rating for NovoCure (NASDAQ: NVCR) was provided by Piper Sandler, and NovoCure reiterated their overweight rating.
When was the last upgrade for NovoCure (NVCR)?
The last upgrade for NovoCure Ltd happened on August 8, 2023 when Piper Sandler raised their price target to $45. Piper Sandler previously had a neutral for NovoCure Ltd.
When was the last downgrade for NovoCure (NVCR)?
The last downgrade for NovoCure Ltd happened on August 28, 2023 when HC Wainwright & Co. changed their price target from N/A to $25 for NovoCure Ltd.
When is the next analyst rating going to be posted or updated for NovoCure (NVCR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NovoCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NovoCure was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating NovoCure (NVCR) correct?
While ratings are subjective and will change, the latest NovoCure (NVCR) rating was a reiterated with a price target of $25.00 to $28.00. The current price NovoCure (NVCR) is trading at is $12.23, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.